

**Maricopa Integrated Health Systems
Formulary Prior Auth Criteria**

Drug: Didronel (Etidronate disodium)

Therapy:

Is indicated for the treatment of symptomatic Paget's disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury. Didronel is not approved for the treatment of osteoporosis

Inclusions:

A) Paget's disease

- 1) Two of the following symptoms needs to be present

Bone pain and/or deformity
Decreased mobility
Bone fractures

- 2) Bone scan indicating pagetic lesions

B) Recent total hip replacement surgery or spinal cord injury with signs of heterotopic ossification

- 1) Localize pain/inflammation
- 2) Elevated skin temperature
- 3) Redness
- 4) X-ray or bone scan
- 5) Blood tests

Risk Factors/Contraindications:

Patients should maintain an adequate nutritional status, particularly an adequate intake of calcium and vitamin D

Authorization:

Paget's Disease- three months.

Retreatment- initiated only when member has been Didronel free for 90 days and there is still biochemical, symptomatic or other evidence of active disease process- six months

Heterotopic ossification:

- 1) **Total hip-** four months total
- 2) **Spinal cord injury-** three months total

Medical Director _____

Date _____